Fujirebio Europe Receives Distribution Rights to Market Self-screen's PreCursor-M+ Methylation-specific Molecular Assay, a Powerful Solution to Identify Women at High Risk for Cervical Cancer
Fujirebio Europe and Self-screen B.V. today announce a commercial collaboration around the distribution of the PreCursor-M+ methylation-specific molecular IVD assay from Self-screen B.V. The test is intended for the qualitative detection of elevated methylation levels of cervical cancer biomarkers and may be used as a triage follow-up test of human papillomavirus (HPV) positive women and women with ASCUS/ LSIL cytology results. It complements Fujirebio's HPV-specific molecular test portfolio.
Every year, more than 340,000 women across the world die from cervical cancer1, even though it is a preventable disease. Global efforts to eliminate cervical cancer focus on expanding coverage of HPV vaccination and improving cervical cancer screening. However, within (primary HPV) screening programs it is not possible to clearly distinguish within the positively tested women, those who have persistent and progressing cervical disease and those, for whom the disease might be regressing. The PreCursor-M+ methylation-specific molecular assay has been demonstrated as a sensitive follow-up test to identify HPV positive women with progressing cervical disease in direct need for colposcopy or other follow-up procedures2,3.
“Fujirebio has a long legacy in HPV testing, and it was important for us to bring new and complementary testing solutions to our many customers,” says Christiaan De Wilde, CEO Fujirebio Europe “The methylation test from Self-screen, a well-respected pioneer in convenient and powerful HPV testing solutions, is a perfect example of quickly meeting customer demand with market-leading solutions and strategic partnerships.”
“We are very happy that Fujirebio partners with us to transition into still necessary effective innovations. Both our companies share a long history in HPV diagnostics, so this partnership strengthens our joint ambitions in this field,” says Michelle Meijer, Chief Commercial Officer at Self-screen B.V. ”Our methylation test can improve triage with significantly less over-referrals to the gynecologist and unnecessary treatments, and is compatible with lab- and patient-friendly procedures such as self-sampling.”
The PreCursor-M+ test is validated for samples taken by physicians as well as for samples collected by women (self-sampling), which can largely optimize the testing process and increase the participation rates in screening programs and follow up. Please contact Fujirebio for further information about the local availability of the test.
About Self-screen B.V.
Self-screen B.V., has a long history and track record in translational HPV related research, assay development and commercialization. Currently, the company’s main focus is on cervical (pre)cancer screening and prevention to support full molecular cervical screening and to assist the clinician in management of women with high-grade cervical intraepithelial neoplasia (CIN) with two clinically validated IVD assays, the HPV-Risk-Assay and the PreCursor-M+ test, for screening and triage respectively.
Self-screen’s R&D pipeline focuses on extension of its assays towards other sample types, such as self-collected cervical vaginal specimens or urine, on various platforms and for the detection of other cancer types.
About Fujirebio
Fujirebio is a global leader in the field of high-quality IVD testing. The company has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.
Fujirebio has a long-lasting tradition for developing high-quality routine and truly novel biomarkers. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions covering a variety of disease states.
Global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.
References:
- https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
- Kremer WW, Steenbergen RDM, Heideman DAM, Kenter GG, Meijer CJLM. The use of host cell DNA methylation analysis in the detection and management of women with advanced cervical intraepithelial neoplasia: a review. BJOG 2021;128:504-514
- Bonde J. et al. Int. J. Cancer. 2021;148:396-405. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005258/en/
Contact information
Fujirebio Europe N.V.
T +32 (0)9 329 13 29
info@fujirebio.com
www.fujirebio.com
Self-screen B.V.
T +31 (0)20 444 4070
info@self-screen.nl
www.self-screen.nl
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VeriSilicon Launches the Industry-Leading Automotive-Grade Intelligent Driving SoC Design Platform29.4.2025 03:00:00 EEST | Press release
VeriSilicon (688521.SH) recently announced that its automotive-grade high-performance intelligent driving system-on-chip (SoC) design platform has been verified and successfully implemented in customer projects. Leveraging VeriSilicon’s Silicon Platform as a Service (SiPaaS) business model, this platform provides robust technical support for high-performance computing applications such as autonomous driving and advanced driver assistance systems (ADAS). VeriSilicon’s chip design process has obtained ISO 26262 automotive functional safety management system certification, enabling the company to provide global customers with one-stop custom service for their automotive chips that meet functional safety requirements. Combined with its extensive portfolio of automotive-grade IPs and complete intelligent driving software platform, VeriSilicon offers end-to-end support from chip design and verification to automotive certification, including safety requirement analysis, architecture design, a
EU Authorisation Allows for Fermented Rapeseed Cake to Be Applied in Food29.4.2025 00:59:00 EEST | Press release
Most people recognise the yellow, fragrant rapeseed fields that adorn the landscape in spring. But few know that rapeseed cake was banned as food grade until today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428371892/en/ Today is a special day for Danish FERM FOOD ApS, which has received the EU Commission's authorisation to use fermented rapeseed cake as a food ingredient (Left: Founder and CEO Jens Legarth, right: Head of Development Søren Lange). Rapeseed was banned – until today Rapeseed, also known as Canola, is primarily grown for its oil-rich seeds, which are pressed into cooking oil. While you can fill the pan with rapeseed oil, the remaining protein-rich press cake is strictly forbidden for human consumption in the EU until today. Therefore, rapeseed cake is primarily used for feed and biogas. The EU rule that prohibits rapeseed for consumption is called Novel Food and means that only foods that have been con
IFF Pharma Solutions to Showcase Portfolio at Excipient World 202529.4.2025 00:00:00 EEST | Press release
IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, will showcase its sustainable solutions at Excipient World 2025. The team will feature sustainable innovations, controlled-release formulations, and nitrosamine risk mitigation solutions at booth 205 from May 13-14, Gaylord National Resort and Convention Center, National Harbor, Maryland, USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428283122/en/ “At IFF Pharma Solutions, we believe sustainability is not just a responsibility but an opportunity to innovate and inspire,” said Dr. Anne Adden, global strategic marketing director for sustainability and dietary supplements. “We are committed to creating solutions that not only meet the needs of today but also pave the way for a healthier, more sustainable future. Our team of problem-solvers and experts is redefining what it means to lead in sustainable healthcare.” Building on over 75 years of ind
KILL Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill28.4.2025 23:34:00 EEST | Press release
Svante requests that their press release NewsItemId: 20250428544430 “Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill” be killed. The release was issued prematurely by Svante. A replacement release will be issued within the next 48 hours.
Winka Dubbeldam Appointed Director and CEO of SCI-Arc28.4.2025 21:50:00 EEST | Press release
The Southern California Institute of Architecture (SCI-Arc) is thrilled to share that Prof. Winka Dubbeldam has been appointed as the next Director and Chief Executive Officer of SCI-Arc. A globally recognized Dutch architect, educator, and leader in design innovation, Winka will officially assume the role on September 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428994100/en/ Winka Dubbeldam Winka brings more than three decades of experience to the forefront of architectural practice and education. She is a full Professor of Architecture and served as Chair at the University of Pennsylvania Stuart Weitzman School of Design for ten years (2013–2023). Previously she initiated and directed the Post-Professional Architecture program for ten years (2003–2013), providing international students with innovative design skills, cutting-edge theoretical and technological knowledge necessary for a productive and innovativ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom